Replies to post #503210 on NorthWest Biotherapeutics Inc (NWBO)

[Dan88]

Because the vast majority of crossovers are composed of mesenchymal GBM while treatment arm consists of much much less mesenchymal GBM.

If you are interested, you should compare OS of mesenchymal GBMs between the crossovers and the treatment.

Contrary to SOC or other treatments where mesenchymal GBMs are the worst group in terms of OS, in our DCVax-L trial, patients with mesenchymal GBMs have experienced the best OS outcomes, regardless the arms.